靶向肿瘤免疫微环境可能成为侵袭性垂体腺瘤的潜在治疗方式

One hundred and three patients with PA who underwent surgery at a single institution were retrospectively identified. The infiltration of macrophages and T-lymphocytes was quantitatively assessed.

The number of CD68+ macrophages was positively correlated with Knosp ( p = 0.003) and MMP-9 expression grades ( p = 0.00). The infiltration of CD163+ macrophages differed among Knosp ( p = 0.022) and MMP-9 grades ( p = 0.04). CD8+ tumor-infiltrating lymphocytes (TILs) were also positively associated with Knosp ( p = 0.002) and MMP-9 grades ( p = 0.01). Interestingly, MGMT expression was positively correlated with MMP-9 staining extent ( p = 0.000). The quantities of CD8+ TILs ( p = 0.016), CD68+ macrophages ( p = 0.000), and CD163+ macrophages ( p = 0.043) were negatively associated with MGMT expression levels. The number of CD68+ macrophages in the PD-L1 negative group was significantly more than that in the PD-L1 positive group ( p = 0.01). The rate of PD-L1 positivity was positively correlated with the Ki-67 index ( p = 0.046) and p53 expression ( p = 0.029).

Targeted therapy for macrophages and CD8+ TILs could be a helpful treatment in the future for aggressive PA. Anti-PD-L1 therapy may better respond to PAs with higher Ki-67 and p53 expression and more infiltrating CD68+ macrophages. Multiple treatment modalities, especially combined with immunotherapy could become a novel therapeutic strategy for aggressive PA.